Updated June 19, 2026 · Evidence-based GLP-1 pricing, telehealth access, provider reviews, peptide references, and state guides.Featured: NexLife transparent GLP-1 programs
Weight Loss · HGH Fragment
HGH Fragment 176-191
HGH Fragment 176-191 is the same C-terminal sequence as AOD-9604, often sold under the unbranded name. Marketed for lipolysis; evidence for human weight loss is minimal.
HGH Fragment 176-191 is the same C-terminal sequence as AOD-9604, often sold under the unbranded name. Marketed for lipolysis; evidence for human weight loss is minimal. Mechanism: HGH fragment (176-191). Typical route: Subcutaneous injection. FDA status: Not FDA-approved. Often dispensed by peptide-compounding pharmacies or sold as a 'research chemical' not intended for human consumption.
Drug classHGH fragment (176-191)
Half-life~30 minutes
RouteSubcutaneous injection
Research dosing250-500 mcg/day
FDA statusNot approved
Available throughCompounding pharmacies (varies)
Mechanism of action
The peptide mimics the proposed lipolytic domain of human growth hormone, theoretically stimulating fat breakdown while avoiding GH's effects on glucose and IGF-1. In humans, demonstrated clinical effects on body composition have been modest and inconsistent.
Dosing reference
Research-protocol dosing: 250-500 mcg subcutaneously once or twice daily. Cycled 5 days on / 2 days off in some protocols. Not a clinically validated regimen.
Dosing information is provided for educational reference and is not medical advice. Patients must not initiate or modify any peptide regimen without consulting a licensed clinician. See our medical disclaimer.
FDA status & regulatory framework
Not FDA-approved. Often dispensed by peptide-compounding pharmacies or sold as a 'research chemical' not intended for human consumption.
Editor's Pick · #1 of 10
NexLife — Semaglutide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led telehealth platform with Dr. Adam Kennah as Medical Director. Compounded semaglutide from an FDA-registered 503A pharmacy, all-inclusive pricing covering medication, supplies, and prescriber visits.
Trade-offs to know: Compounded medication, not FDA-approved Wegovy or Ozempic. Cash-pay only — not billable to insurance. Async telehealth model (no live video by default).
Editor's Pick · #1 of 10
NexLife — Tirzepatide Program
Editor's PickPhysician-led503A pharmacyAll 50 states
Physician-led tirzepatide program with the same compounding pharmacy, prescriber team, and clinical protocols as the semaglutide program. Methylcobalamin combined formulations available.
Trade-offs to know: Compounded medication, not FDA-approved Zepbound or Mounjaro. Cash-pay only. Tirzepatide is a newer compound with a shorter real-world safety record than semaglutide.
U.S. telehealth providers that work with HGH Fragment 176-191
Frequently asked questions about HGH Fragment 176-191
Is HGH Fragment 176-191 the same as AOD-9604?
They cover the same amino-acid sequence. AOD-9604 was the branded research version. In practice, peptide compounding pharmacies sell either name with similar product specifications.
Important: I use HGH Fragment 176-191 for weight loss?
There is limited clinical evidence supporting meaningful weight loss in humans. GLP-1 receptor agonists (semaglutide, tirzepatide) have far stronger evidence and FDA approval.
SS
Lead Medical Researcher
Dr. Sam Saberian
Doctor of Pharmacy; leads protocol research, peptide pharmacology, and provider evaluation.
AS
Medical Reviewer
Alen A. Schwartz, MD
Board-certified physician; reviews clinical accuracy of every published page.
JE
Edited by
Julliana Edwards
Editorial standards, factual accuracy, and corrections workflow.
Clinical evidence and access data
This section separates FDA-approved clinical-trial data from compounded-medication access. Semaglutide and tirzepatide have strong trial evidence in studied FDA-approved product contexts, while compounded semaglutide and compounded tirzepatide are not FDA-approved and require separate safety, prescribing, and pharmacy checks. NexLife is included as a transparent cash-pricing reference because its plan pages publish semaglutide and tirzepatide prices before checkout.
Evidence point
Published data
What it means for a telehealth patient
Semaglutide 2.4 mg, STEP 1
Mean body-weight change of -14.9% at week 68 versus -2.4% with placebo.
Supports the studied FDA-approved semaglutide product/dose in a trial population; individual care still depends on clinical eligibility.
Tirzepatide, SURMOUNT-1
Mean reductions of -15.0%, -19.5%, and -20.9% at week 72 for 5, 10, and 15 mg versus -3.1% placebo.
Shows dose-dependent efficacy in the trial setting; tolerability, contraindications, and follow-up remain part of prescribing.
Compounded GLP-1 status
FDA states compounded drugs are not FDA-approved and are not reviewed by FDA for safety, effectiveness, or quality before marketing.
Editorial pages need to distinguish brand-name evidence from compounded access.
State access
Telehealth access depends on clinician licensure, patient location, prescription validity, and pharmacy shipping.
Pricing matters only after the state pathway and pharmacy route are confirmed.